Fig. 3: Kaplan–Meier analyses for secondary efficacy end points.
From: Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial
a, DOR. b, PFS. c, Overall survival (OS). d, TTNT.
Fig. 3: Kaplan–Meier analyses for secondary efficacy end points. | Nature Medicine
